Thyrocare Technologies · NSE: THYROCARE · BSE: 539871

Q1 FY21 results · Apr–Jun 2020

Thyrocare Technologies reported revenue from operations of ₹56.27 crore (down 48.7% from Q1 FY20) and net profit of ₹0.23 crore (down 99.2% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.

Consolidated · ₹ crore
ItemQ1 FY21Q1 FY20YoYQ4 FY20QoQ
Revenue from operations56.27109.73−48.7%101.44−44.5%
Other income1.222.36−48.3%2.06−40.8%
Total income57.49112.09−48.7%103.50−44.5%
Profit before share of associates & JVs and tax2.3940.15−94.0%17.59−86.4%
Share of profit/(loss) of associates & JVs(0.26)0.18(0.02)
Net profit for the period0.2327.47−99.2%(1.59)Turned profit
EPS, basic (₹)0.045.20−99.2%(0.30)Turned profit
Net margin (%)0.425.0-1.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ1 FY21Q1 FY20YoYQ4 FY20QoQ
Revenue from operations54.40100.50−45.9%93.62−41.9%
Other income1.493.35−55.5%2.47−39.7%
Total income55.89103.85−46.2%96.09−41.8%
Profit before tax6.3242.96−85.3%(18.27)Turned profit
Net profit for the period4.4230.10−85.3%(18.09)Turned profit
EPS, basic (₹)0.845.70−85.3%(3.43)Turned profit
Net margin (%)8.130.0-19.3
Consolidated
Filed with BSE
01 Aug 2020, 14:32 IST
Board meeting
31 Jul 2020
Period
01 Apr 2020 to 30 Jun 2020
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
01 Aug 2020, 14:32 IST
Board meeting
31 Jul 2020
Period
01 Apr 2020 to 30 Jun 2020
Review status
Unaudited
Source
XBRL filing on BSE